1) Funding amount is 1,349 million yen (total paid-in amount 1,361.4 million yen, net proceeds rough 1,349.4 million yen) 2) Potential shares: 10,000,000 shares, initial exercise price 136 yen, lower limit 81 yen, exercise price linked to a adjustment clause 3) Allottees: Okasan Securities, allotment date: 2026-10-05, trading halt period 4) Primary use: In vivo CAR-T related costs and clinical development for NIB103\/NIB104 and next-generation manufacturing methods 5) Maximum shareholder dilution expected up to 23.0%<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4893","jir_company_name":"Nol Immunoon Biotechnology Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4893-20260918-01.pdf","jir_short_summary":"1) Funding amount is 1,349 million yen (total paid-in amount 1,361.4 million yen, net proceeds rough 1,349.4 million yen) 2) Potential shares: 10,000,000 shares, initial exercise price 136 yen, lower limit 81 yen, exercise price linked to a adjustment clause 3) Allottees: Okasan Securities, allotment date: 2026-10-05, trading halt period 4) Primary use: In vivo CAR-T related costs and clinical development for NIB103\/NIB104 and next-generation manufacturing methods 5) Maximum shareholder dilution expected up to 23.0%","jir_summary":"### Overview of the financing\nThe issuance of these stock acquisition rights is a financing through a third-party allotment, with Okasan Securities Co., Ltd. as the allottees. The total\u52df\u96c6\u7dcf\u984d is 1,361,400,000 yen, with net proceeds of approximately 1,349,400,000 yen. The number of underlying shares is 10,000,000, with an initial exercise price of 136 yen and a lower limit of 81 yen; the exercise price will adjust in line with movements in the Tokyo Stock Exchange closing price due to the adjustment provision. Dilution is estimated at up to 23.0%.\n\n### Use of funds and outlook\nThe funds will be allocated to in vivo CAR-T research and development costs of 600 million yen, NIB103 clinical development costs of 500 million yen, NIB104 R&D costs of 125 million yen, and next-generation manufacturing process R&D costs of 124 million yen. Through future growth investments, we will advance the clinical development of NIB103\/NIB104 and accelerate in vivo CAR-T development to enhance the value of the CAR-T business.","jir_financial_highlights":"Funding amount: 1,349\u767e\u4e07\u5186 (\u4e0d\u660e)\n\u6f5c\u5728\u682a\u5f0f\u6570: 10,000,000\u682a (\u4e0d\u660e)\n\u884c\u4f7f\u4fa1\u984d\uff08\u521d\u671f\uff09: 136\u5186 (\u4fee\u6b63\u65e5\u4ee5\u964d\u66f4\u65b0)\n\u4e0b\u9650\u884c\u4f7f\u4fa1\u984d: 81\u5186 (\u4e0d\u660e)\n\u5e0c\u8584\u5316\u6700\u5927\u682a\u5f0f\u6570: 10,000,000\u682a (\u6700\u592723.0%\u306e\u8b70\u6c7a\u6a29\u6bd4\u7387)","jir_category":"","jir_hashtags":"\u30ce\u30a4\u30eb\u30a4\u30df\u30e5\u30fc\u30f3\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u682a\u5f0f\u4f1a\u793e, \u65b0\u682a\u4e88\u7d04\u6a29, \u8cc7\u672c\u653f\u7b56","jir_key_figures":"1,349\u767e\u4e07\u5186: \u8abf\u9054\u8cc7\u91d1\uff08\u5dee\u5f15\u624b\u53d6\u6982\u7b97\u984d\uff09\n10,000,000\u682a: \u6f5c\u5728\u682a\u5f0f\u6570\n81\u5186\u2013136\u5186: \u884c\u4f7f\u4fa1\u984d\u306e\u7bc4\u56f2\uff08\u4e0b\u965081\u5186\u3001\u521d\u671f136\u5186\u3001\u4fee\u6b63\u6761\u9805\u3042\u308a\uff09","jir_meta_title":"\u3010\u30ce\u30a4\u30eb\u30a4\u30df\u30e5\u30fc\u30f3\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u3011New Stock Subscription Rights Issuance Notice\uff5c2026\u5e7410\u67085\u65e5","jir_meta_description":"Nol Immunoon Biotechnology issues stock subscription rights through third-party allotment. Funding amount: 1,349 million yen; underlying shares: 10 million; use of funds: in vivo CAR-T research and development, clinical development, and next-generation manufacturing investments.","jir_og_title":"\u3010\u30ce\u30a4\u30eb\u30a4\u30df\u30e5\u30fc\u30f3\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u3011New Stock Subscription Rights Issuance Notice\uff5c2026\u5e7410\u67085\u65e5","jir_og_description":"Funding of 1,349 million yen, underlying shares of 10 million; stock subscription rights with exercise price adjustment clause allotted to Okasan Securities. Planned use for in vivo CAR-T development and related costs.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59659,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-115457","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n